Potential impact on mental health in patients with treatment-resistant schizophrenia – clozapine augmentation with long-acting parenteral antipsychotics: a case series

Česká verze

Authors: M. Nováková ^1,2*; T. Hammer ^1,3*; E. Nováková ¹; M. Mayerová ⁴; L. Ustohal ^1,4; PharmDr. Bc. Hana Kotolová, Ph.D. ¹
Authors place of work: Ústav farmakologie a toxikologie, Farmaceutická fakulta, Masarykova univerzita, Brno Palackého třída 1946/1, 612 00 Brno e-mail: kotolovah@pharm. muni. cz ¹; Ústav aplikované farmacie, Farmaceutická fakulta, Masarykova univerzita, Brno ²; Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno ³; Psychiatrická klinika Lékařské fakulty Masarykovy Univerzity a Fakultní nemocnice Brno ⁴
Published in the journal: Čes. slov. Farm., 2023; 72, 277-287
Category: Původní práce
doi: https://doi.org/10.5817/CSF2023-6-277

Summary

Introduction: The rate of pharmacoresistance among in patients diagnosed with schizophrenia is around 30%. Clozapineis the drug of choice for these patients; however, an adequate response to treatment doesn’t always occur. One of the possible augmentation approaches, specifically for non-adherent patients, is the administration of long-acting parenteral antipsychotics. Our goal was to evaluate previous experiences of administering a combination of the atypical antipsychotic clozapine and long-acting injectable antipsychotics to pharmacoresistant patients at the Department of Psychiatry the Czech Republic and to assess the safety and effectiveness of such administration.

Methods: A retrospective evaluation of patient case studies was conducted for those who were hospitalized in the Ward for the therapy of Psychotic disorders between 2016 and 2020 and had a medication history of combining clozapine and depot antipsychotics.

Results: Over half of the patients had no illness relapses during the observed period. The clinical manifestation of adverse effects from combination therapy appears low in our patient sample, primarily involving mild and pharmacologically manageable side effects (tachycardia). Only one of the cases recorded neutropenia, which led to discontinuation of clozapine; the patient was maintained on long-acting injectable antipsychotics medication.

Conclusion: From our findings, it can be inferred that augmenting clozapine with depot antipsychotics is a potential therapeutic intervention that pharmacoresistant patients could benefit from. However, it is essential to emphasize that this therapeutic approach should only be administered after carefully considering the patient’s existing treatment. It should be strictly individualized based on the treating physician’s or clinical pharmacist’s sufficient professional experience.

Keywords:

pharmacoresistance – Schizophrenia – clozapine – long-acting antipsychotics – nonadherence

Zdroje

Jauhar S., Johnstone M., McKenna P. J. Schizophrenia. Lancet 2022; 399(10323), 473–486. doi: 10.1016/ S0140-6736(21)01730-X
World Health Organization. Schizophrenia. WHO website. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia (10. 1. 2022).
Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther. Adv. Psychopharmacol. 2018; 8, 303–318.
Kane J. M., Agid O., Baldwin M. L., Howes O., Lindenmayer J. P., Marder S., Olfson M., Potkin S. G., Correll C. U. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J. Clin. Psychiatry 2019; 80(2), 18com12123.
Taylor D. M. Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? CNS Drugs 2017; 31, 177–180. doi: 10.1007/s40263-017-0411-6
Faden J. Treatment-Resistant Schizophrenia: A Brief Overview of Treatment Options. J. Clin. Psychiatry 2019; 80(4), 18ac12394. doi: 10.4088/JCP.18ac12394
Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry 2007; 18(1), 39–60.doi: 10.1177/0957154X07070335. PMID: 17580753.
Griffith R. W., Saameli K. Letter: Clozapine and agranulocytosis. Lancet 1975; 2(7936), 657. doi: 10.1016/s0140-6736(75)90135-x. PMID: 52022.
Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988; 45, 789–796. doi: 10.1001/archpsyc.1988.01800330013001
Meltzer H. Y., Alphs L., Green A. I., Altamura A. C, Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M. Z., Kane J., Krishnan R., Lindenmayer J. P., Potkin S. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality inschizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003; 60(1), 82–91. doi: 10.1001/archpsyc.60.1.82. Erratum in: Arch. Gen. Psychiatry 2003; 60(7), 735.
Leucht S., Corves C., Arbter D., Engel R. R., Li C., Davis J. M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657), 31–41. doi: 10.1016/S0140-6736(08)-61764-X
World Health Organization. Model List of Essential Medicines – 22nd List, 2021. Geneva: World Health Organization; 2021(WHO/MHP/HPS/EML/2021.02). Licence: CC BY-NC-SA 3.0 IGO.
Grimminck R., Oluboka O., Sihota M., Rutherford D. L, Yeung H. Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices. Prim. Care Companion CNS Disord. 2020; 22(4), 19m02560. doi: 10.4088/PCC.19m02560. PMID: 32678523
Friedman J. H., Lannon M. C. Clozapine‐responsive tremor in Parkinson’s disease. Mov. Disord. 1990; 5, 225–229.
Bonuccelli U., Ceravolo R., Salvetti S., D’Avino C., Del Dotto P., Rossi G., Murri L. Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 1997; 49, 1587–1590.
Trosch R. M., Friedman J. H., Lannon M. C., Pahwa R., Smith D., Seeberger L. C., O’Brien C. F, LeWitt P. A., Koller W. C.Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience. Mov. Disord. 1998; 13, 377–382.
Psychosis and schizophrenia in adults. The NICE guideline on treatment and management – Updated edition 2014 [online]. Available from: https://www.nice.org.uk/ guidance/cg178/evidence/full-guide-line-490503565. (4. 5. 2023).
Myles N., Myles H., Xia S., Large M., Kisely S., Galletly C., Bird R., Siskind D. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr. Scand. 2018; 138(2), 101–109. doi: 10.1111/ acps.12898
Couchman L., Morgan P. E., Spencer E. P., Flanagan R. J. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther. Drug Monit. 2010; 32(4), 438–447. doi: 10.1097/FTD.0b013e3181dad1fb
Yaw T. K., Fox S. H., Lang A. E. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Mov.Disord. Clin. Pract. 201530; 3(2), 116–124. doi: 10.1002/mdc3.12266
de Berardis D., Rapini G., Olivieri L., Di Nicola D., Tomasetti C., Valchera A., Fornaro M., Di Fabio F., Perna G., Di Nicola M., Serafini G., Carano A., Pompili M., Vellante F., Orsolini L., Martinotti G., Di Giannantonio M. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther. Adv. Drug Saf. 2018; 9(5), 237–256. doi:10.1177/2042098618756261
Siskind D., Siskind V., Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data froma Systematic Review and Meta-Analysis. Can. J. Psychiatry 2017; 62(11), 772–777. doi: 10.1177/0706743717718167
Roerig J. L. Clozapine augmentation strategies. Ment. Health Clin. 2019 Nov 27; 9(6), 336–348. doi: 10.9740/ mhc.2019.11.336
Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J. Psychiatry 2021; 11(8), 429–448. doi: 10.5498/wjp.v11.i8.429
Muscatello M. R., Bruno A., de Fazio P., Segura-Garcia C., Pandolfo G., Zoccali R. Augmentation strategies in partialresponder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opin. Pharmacother. 2014; 15(16), 2329–2345. doi:10.1517/14656566.2014.956082
Buckley P., Miller A., Olsen J., Garver D., Miller D. D., Csernansky J. When symptoms persist: clozapine augmentation strategies.Schizophr. Bull. 2001; 27(4), 615–628. doi: 10.1093/oxfordjournals.schbul.a006901
de Berardis D., Fornaro M., Anastasia A., Vellante F., Valchera A., Cavuto M., Perna G., Di Nicola M., Serafini G., Carano A.,Pompili M., Orsolini L., Tomasetti C., Di Emidio G., Martinotti G., Di Giannantonio M. When clozapine fails: Augmentationstrategies in the management of clozapine-resistant schizophrenia. In: Kim Y. K. (Eds.) Treatment resistance in psychiatry. Singapore:Springer Nature Singapore Pte Ltd, 2019; 349–367. doi: 10.1007/978-981-10-4358-1_23
Bartoli F., Crocamo C., Di Brita C., Esposito G., Tabacchi T. I., Verrengia E., Clerici M., Carrà G. Adjunctive second-generation antipsychotics for specific symptom domains ofschizophrenia resistant to clozapine: A meta-analysis. J. Psychiatr. Res. 2019; 108, 24–33. doi: 10.1016/j.jpsychires.2018.11.005
Miyamoto S., Jarskog L. F., Fleischhacker W. W. Schizophrenia: when clozapine fails. Curr. Opin. Psychiatry 2015; 28, 243–248. doi: 10.1097/YCO.0000000000000159
Davis M. C., Fuller M. A., Strauss M. E., Konicki P. E, Jaskiw G. E. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr. Scand. 2014; 130, 30–39. doi: 10.1111/acps.12233 [Epub 2013 Dec 2].
Krivoy A., Malka L., Fischel T., Weizman A., Valevski A. Predictors of clozapine discontinuation in patients with schizophrenia. Int.Clin. Psychopharmacol. 2011; 26(6), 311–315. doi: 10.1097/YIC.0b013e32834ab34c
Legge S. E., Hamshere M., Hayes R. D., Downs J., O’Donovan M. C, Owen M. J, Walters J. T. R, MacCabe J. H. Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. Schizophr. Res. 2016; 174(1–3), 113–119. doi: 10.1016/j.schres.2016.05.002
Pai N. B., Vella S. C. Reason for clozapine cessation. Acta Psychiatr. Scand. 2012; 125(1), 39–44. doi: 10.1111/j.160leucht0-0447.2011.01776.x
Taylor D. M., Douglas-Hall P., Olofinjana B., Whiskey E., Thomas A. Reasons for discontinuing clozapine: matched, case-controlcomparison with risperidone long-acting injection. Br. J. Psychiatry 2009; 194(2), 165–167. doi: 10.1192/bjp.bp.108.051979
Leucht C., Heres S., Kane J. M., Kissling W., Davis J. M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011; 127(1–3), 83–92. doi: 10.1016/j.schres.2010.11.020
Galletly C., Castle D., Dark F., Humberstone V., Jablensky A., Killackey E., Kulkarni J., McGorry P., Nielssen O., Tran N. Royal Australian and New Zealand College of Psychiatrists, Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39, 1–30.
Kuipers E., Yesufu-Udechuku A., Taylor C., Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidelines 2014. BMJ 2014; 348, g1173.
Kishimoto T., Nitta M., Borenstein M., Kane J. M., Correll C. U. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J. Clin. Psychiatry 2013; 74(10), 957–965. doi: 10.4088/JCP.13r08440
Kaplan G., Casoy J., Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer. Adherence 2013; 7(7), 1171–1180. doi: 10.2147/PPA.S53795
Manchanda R., Chue P., Malla A., Tibbo P., Roy M. A., Williams R., Iyer S., Lutgens D., Banks N. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can. J. Psychiatry 2013; 58(Suppl 1), 5S–13S. Long-acting injectable antipsychotics: evidence of effectiveness and use.
Kim S. H., Jung D. CH., Ahn Y. M., Kim Y. S. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. J. Psychopharmacol. 2010; 24, 981–986. doi: 10.1177/0269881109348174
Baruch N., Das M., Sharda A., Basu A., Bajorek T., Ross C. C., Sengupta S., Larkin F., Young S. An evaluation of the use of olanzapine pamoate depot injection in seriously violent menwith schizophrenia in a UK high-security hospital. Ther. Adv. Psychopharmacol. 2014; 4, 186–192. doi:10.1177/2045125314531982
Maia-de-Oliveira J. P., Nunes E. A., Ushirohira J. M., Machado-de-Sousa J. P., Bressan R. A., Hallak J. E. Paliperidonepalmitate for refractory and clozapine-resistant schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2015; 27, e14–e16. doi: 10.1176/appi.neuropsych.13120374 [Epub 2014 Dec 12].
Kasinathan J., Sharp G., Barker A. Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community. Ther. Adv. Psychopharmacol. 2016; 6, 301–307. doi: 10.1177/2045125316656319
Sepede G., Di Iorio G., Spano M. C., Lorusso M., Sarchione F., Santacroce R., Salerno R. M., Di Giannantonio M. A Case of Resistant Schizophrenia Successfully Treated With Clozapine/Long-acting Injectable Aripiprazole Combination. Clin. Neuropharmacol. 2016; 39, 322–324. doi: 10.1097/WNF.0000000000000191
Oriolo G., Dominguez I., Fortea A., Bioque M., Bernardo M. Combination of clozapine with paliperidone in treatment resistant schizophrenia. Eurneuropsychopharmacol. 2016; 26, S536.
Souaiby L., Gauthier C., Rieu C., Krebs M. O., Advenier-Iakovlev E., Gaillard R. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. Schizophr. Res. 2017; 188, 89–91. doi: 10.1016/j.schres.2017.01.036
Bioque M., Parellada E., García-Rizo C., Amoretti S., Fortea A., Oriolo G., Palau P., Boix-Quintana E., Safont G., Bernardo M. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Eur. Psychiatry 2020; 63, e71. doi: 10.1192/j.eurpsy.2020.72
Caliskan A. M., Karaaslan M., Inanli I., Caliskan S., Arslan M., Esra Cicek I., Eren I. The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study. Int. Clin. Psychopharmacol. 2021; 36, 30–33.
Ustohal L., Přikryl R. Léčba rezistentní schizofrenie v praxi. Psychiat. pro Praxi 2009; 10(4), 176–179.
Patel K. R., Cherian J., Gohil K., Atkinson D. Schizophrenia: overview and treatment options. P. T. 2014; 39(9), 638–645
Brianne M., Newman M. D., William J., Newman M. D. Rediscovering clozapine: Adverse effects develop – what should you do now? Current Psychiatry 2016; 15(8), 40–46, 48–49.
Iqbal E., Govind R., Romero A., Dzahini O., Broadbent M., Stewart R., Smith T., Kim C. H., Werbeloff N., MacCabe J. H.,Dobson R. J. B., Ibrahim Z. M. The side effect profile of clozapine in real world data of three large mental health hospitals. PLoS One 2020; 15(12), e0243437. doi: 10.1371/journal.pone.0243437
Seppälä N. Clozapine-clinical studies on adverse effects and interactions. Academic dissertation. Tampere: Tampere University press, 2014. Available from: https://urn.fi/URN:ISBN:978-951-44-9565–9566 (21. 3. 2023).